LOTTE Biologics Celebrates Completion of Songdo Bio Campus Plant 1 with Global Leaders
LOTTE Biologics Celebrates a New Era in K-Bio
On November 18, 2026, LOTTE Biologics commemorated the completion of Plant 1 at the Songdo Bio Campus in Incheon, South Korea, with a ceremony attended by approximately 300 distinguished guests, including key figures from both the company and the government. This event marks a crucial milestone in LOTTE Biologics' mission to assert its presence as a competitive player in the global Contract Development and Manufacturing Organization (CDMO) market.
The ceremony featured notable attendees such as Dong-bin Shin, Chairman of LOTTE Group; CEO James Park; CEO Yooyeol Shin; and various other dignitaries, including Incheon Mayor Park Chan-dae. Even Prime Minister Han Seong-sook provided her congratulations through a video message, emphasizing the significance of this new facility in enhancing Korea's position in the biopharmaceutical landscape.
James Park opened the ceremony with an inspiring address, highlighting that the plant was “GMP Ready” six months ahead of schedule—a testament to the hard work and dedication of the entire team. He expressed confidence that the new facility would serve as a firm foundation for LOTTE Biologics as they seek to extend their reach into international markets. His vision for the company embodies a relentless pursuit of quality and a genuine commitment to improving human health through innovative biopharmaceutical solutions.
CEO Yooyeol Shin reiterated the project's importance, describing it as pivotal not just for the company, but for the overall enhancement of Korea's bio manufacturing capabilities. Emphasizing their vision of becoming the benchmark for next-generation CDMOs, he assured that LOTTE Biologics would deliver quality and trustworthy partnerships with their clients in a competitive environment.
Chairman Dong-bin Shin expressed his strong belief that the bio sector stands as a future growth engine for the LOTTE Group and recognized Plant 1 as a vital stepping stone toward advancing the competitiveness of Korea’s bio industry. His strategic vision includes creating quality job opportunities and nurturing talent while fostering collaborative relationships with governmental entities and industry partners.
The Songdo Bio Campus covers an impressive total floor area of around 99,558 square meters, incorporating essential facilities such as production and utility buildings, a welfare building, and a wastewater treatment plant. With a remarkable biopharmaceutical production capacity of 120,000 liters, this facility becomes a cornerstone for commercial pharmaceutical production. Following its official approval for use in June 2026, LOTTE Biologics is now in the process of preparing for full-scale commercial operations, expected to start in 2027.
In his remarks, Incheon Mayor Park Chan-dae reiterated his vision for Incheon's bio industry and acknowledged the substantial impact that LOTTE Biologics' new plant would have on the region, positioning it as a hub for global biotech innovation. He expressed optimism that the integration of Incheon's research and development resources with the company’s advanced production capabilities would facilitate the growth and competitiveness of the local bio industry.
As LOTTE Biologics prepares to expand its presence in the global CDMO sector, the official launch of Plant 1 sets the stage for a new chapter in their operational strategy, reinforcing their commitment to innovate and excel within the biopharmaceutical sphere. By leveraging their operational knowledge from the U.S., LOTTE Biologics is not only enhancing its own production capacities but is also poised to contribute significantly to elevating the standard of biopharmaceutical manufacturing in Korea and beyond.
Through these advancements, LOTTE Biologics stands firmly on the path to redefine the landscape of biopharmaceutical production, ensuring a healthier future for patients worldwide. This momentous occasion embodies both a significant achievement and a promise of ongoing innovation and progress in the burgeoning K-Bio arena.